(Q44567910)

4 December 2017

Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis (English)

1 reference

4 December 2017

0 references

Susan I O'shea

1

1 reference

4 December 2017

Jeffrey H Lawson

2

1 reference

4 December 2017

Donal Reddan

3

1 reference

4 December 2017

Michael Murphy

4

1 reference

4 December 2017

Thomas L Ortel

5

1 reference

4 December 2017

language of work or name

1 reference

1 September 2003

1 reference

Journal of Vascular Surgery

4 December 2017

1 reference

4 December 2017

38

1 reference

4 December 2017

3

1 reference

4 December 2017

541-548

1 reference

Hospitalization in dialysis patients

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Vascular access for hemodialysis. Patency rates and results of revision

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

PTFE grafts for hemodialysis access. Techniques for insertion and management of complications

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Vascular access for hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Causes of hemodialysis access failure

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Polytetrafluoroethylene graft survival in hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Angiography of upper extremity access fistulas for dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Survival of prosthetic grafts of different materials after impairment of a native arteriovenous fistula in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Canadian Hemodialysis Morbidity Study

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon?

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Antibodies to topical bovine thrombin correlate with access thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Possible role of systemic inflammatory reaction in vascular access thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Angioplasty/thrombolytic treatment of failing and failed hemodialysis access sites: Comparison with surgical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Antiphospholipid antibodies after surgical exposure to topical bovine thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Heparin-induced thrombocytopenia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Hypercoagulopathy in a hemodialysis patient: are elevations in factors VII and VIII effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Heparin reduces the intimal hyperplasia seen in microvascular vein grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Effect of low molecular weight heparin on intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0741-5214%2803%2900321-5

7 January 2021

10.1016/S0741-5214(03)00321-5

Identifiers

DOI

1 reference

4 December 2017

1 reference